156 related articles for article (PubMed ID: 20019697)
1. Biomarker qualification via public-private partnerships.
Eck SL; Paul SM
Clin Pharmacol Ther; 2010 Jan; 87(1):21-3. PubMed ID: 20019697
[TBL] [Abstract][Full Text] [Related]
2. The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.
Wagner JA; Prince M; Wright EC; Ennis MM; Kochan J; Nunez DJ; Schneider B; Wang MD; Chen Y; Ghosh S; Musser BJ; Vassileva MT
Clin Pharmacol Ther; 2010 May; 87(5):539-42. PubMed ID: 20407460
[TBL] [Abstract][Full Text] [Related]
3. Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors.
Wagner JA; Wright EC; Ennis MM; Prince M; Kochan J; Nunez DJ; Schneider B; Wang MD; Chen Y; Ghosh S; Musser BJ; Vassileva MT
Clin Pharmacol Ther; 2009 Dec; 86(6):619-25. PubMed ID: 19553931
[TBL] [Abstract][Full Text] [Related]
4. Improving health with partnerships between academia and industry.
Desmond-Hellmann S
JAMA Intern Med; 2013 Jun; 173(12):1051-2. PubMed ID: 23609423
[No Abstract] [Full Text] [Related]
5. Promises of biomarkers in drug development--a reality check.
Marrer E; Dieterle F
Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.
Miossec P; Verweij CL; Klareskog L; Pitzalis C; Barton A; Lekkerkerker F; Reiter S; Laslop A; Breedveld F; Abadie E; Flamion B; Dere W; Mpofu S; Goel N; Ethgen D; Mitlak B; Ormarsdóttir S; Rao R; Tsouderos Y; Reginster JY;
Ann Rheum Dis; 2011 Oct; 70(10):1713-8. PubMed ID: 21784723
[TBL] [Abstract][Full Text] [Related]
7. Public-private partnerships for health: their main targets, their diversity, and their future directions.
Widdus R
Bull World Health Organ; 2001; 79(8):713-20. PubMed ID: 11545327
[TBL] [Abstract][Full Text] [Related]
8. Challenges of biomarkers in drug discovery and development.
Goodsaid F
Expert Opin Drug Discov; 2012 Jun; 7(6):457-61. PubMed ID: 22471322
[TBL] [Abstract][Full Text] [Related]
9. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
[TBL] [Abstract][Full Text] [Related]
10. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
11. Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium.
Miller BE; Tal-Singer R; Rennard SI; Furtwaengler A; Leidy N; Lowings M; Martin UJ; Martin TR; Merrill DD; Snyder J; Walsh J; Mannino DM
Am J Respir Crit Care Med; 2016 Mar; 193(6):607-13. PubMed ID: 26745765
[TBL] [Abstract][Full Text] [Related]
12. Qualification of imaging biomarkers for oncology drug development.
Waterton JC; Pylkkanen L
Eur J Cancer; 2012 Mar; 48(4):409-15. PubMed ID: 22226478
[TBL] [Abstract][Full Text] [Related]
13. Allocation of control rights and cooperation efficiency in public-private partnerships: theory and evidence from the Chinese pharmaceutical industry.
Zhang Z; Jia M; Wan D
Int J Health Care Finance Econ; 2009 Jun; 9(2):169-82. PubMed ID: 19360467
[TBL] [Abstract][Full Text] [Related]
14. Public-private partnership: from there to here.
Croft SL
Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S9-14. PubMed ID: 16087204
[TBL] [Abstract][Full Text] [Related]
15. Progress in public-private partnerships to fight neglected diseases.
Gustavsen K; Hanson C
Health Aff (Millwood); 2009; 28(6):1745-9. PubMed ID: 19887415
[TBL] [Abstract][Full Text] [Related]
16. Individual and combined effects of peroxisome proliferator-activated receptor and {gamma} agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers.
Wagner JA; Larson PJ; Weiss S; Miller JL; Doebber TW; Wu MS; Moller DE; Gottesdiener KM
J Clin Pharmacol; 2005 May; 45(5):504-13. PubMed ID: 15831773
[TBL] [Abstract][Full Text] [Related]
17. Leveraging crowdsourcing to facilitate the discovery of new medicines.
Norman TC; Bountra C; Edwards AM; Yamamoto KR; Friend SH
Sci Transl Med; 2011 Jun; 3(88):88mr1. PubMed ID: 21697527
[TBL] [Abstract][Full Text] [Related]
18. Drug patent plan gets mixed reviews.
Butler D
Nature; 2009 Feb; 457(7233):1064. PubMed ID: 19256077
[No Abstract] [Full Text] [Related]
19. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
20. Using controlled clinical trials to learn more about acute drug-induced liver injury.
Watkins PB; Seligman PJ; Pears JS; Avigan MI; Senior JR
Hepatology; 2008 Nov; 48(5):1680-9. PubMed ID: 18853438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
